THE PINK PILL – Review by April Neale

There is a reason the fight over a small pink pill feels so enormous.

On its surface, The Pink Pill: Sex, Drugs & Who Has Control chronicles the battle to bring a medication for women’s low sexual desire to market. At its core, the documentary is about power. It is about who gets to define health, who gets to claim pleasure, and who benefits when women are told to stay quiet about their bodies. It is maddening and relatable. Women all wonder, “What happened to me?” Men always get listened to. Women are dismissed and made to feel wrong for even asking the question.

Directed by Aisling Chin-Yee and premiering at DOC NYC, the film follows entrepreneur Cindy Eckert’s decade-long struggle to win FDA approval for Addyi, the drug frequently labeled “female Viagra.” The nickname is catchy. The comparison is revealing. More than twenty medications for male erectile dysfunction have been approved with relative efficiency. Addyi was stalled, scrutinized, and moralized for years. Why do we want horny women running around? says one FDA executive. You want to throttle the lot as you watch.

The discrepancy is not just bureaucratic. It is ideological.

From the beginning, the film establishes the central injustice. Male sexual performance is framed as essential to identity. If a man cannot perform, it is treated as a crisis of masculinity and a medical emergency. If a woman cannot orgasm, feels pain during intercourse, or loses desire, she is told it is normal. After childbirth. After menopause. After years of marriage. After life happens. Buy some lubricant and try harder. It’s all on you.

The Pink Pill dismantles that normalization. It exposes how medical education and healthcare institutions have long sidelined women’s sexual needs. These same systems have aggressively funded and fast-tracked drugs for men. The film shows regulators raising concerns that women might become drowsy and fall asleep while driving children to school. The subtext is unmistakable: a woman’s primary role is caretaker. Her pleasure is secondary and deeply suspect.

What makes the documentary especially urgent is its timing. Chin-Yee situates Eckert’s fight within a broader political shift. Footage of the 2016 election, the reshaping of the Supreme Court, and the fall of Roe v Wade is not incidental. It underscores a pattern. As the political right has gained power, reproductive rights have narrowed. Abortion access has been curtailed. Conversations about contraception and bodily autonomy have become battlegrounds.

The correlation is not subtle. Movements that seek to limit women’s control over reproduction often also resist conversations about female desire. In conservative and religious circles, sexuality is frequently tethered to procreation and marriage. Female pleasure outside those boundaries is framed as indulgent, destabilizing, even sinful.

Throughout history, many religious doctrines have treated women’s sexuality as something to regulate. Modesty codes, purity culture, and rigid gender roles are not fringe ideas. They are embedded in institutions that shape law and policy. The recent rise of right-leaning political movements has amplified these frameworks. The idealized “tradwife” narrative celebrates domestic submission, childbearing, and withdrawal from public power. Feminism is cast as corrosive. Autonomy is reframed as selfishness.

Against that backdrop, a drug designed to enhance female desire becomes more than medicine. It becomes a symbol.

The Pink Pill makes clear that resistance to Addyi was not solely about clinical data. It was about discomfort. Discomfort with the idea that women might seek sex for pleasure rather than obligation. Discomfort with acknowledging that female libido is not automatically extinguished by age, motherhood, or long-term partnership. Discomfort with women naming dissatisfaction and demanding solutions.

Fear sits at the center of this discomfort. Fear that sexual agency disrupts traditional hierarchies. Fear that a woman who claims her own pleasure might also claim her own economic and political independence. Fear that equality in the bedroom signals equality everywhere.

Eckert’s journey embodies that tension. Outspoken and unapologetic in her trademark pink, she confronts regulators and critics head-on. She marshals advocacy groups and public pressure to expose, as she frames it, gender bias at the FDA. When Addyi finally won approval in 2015, the victory felt seismic. It is proof that persistence can pierce institutional inertia.

Yet the film does not end in triumph alone. It shows how the drug’s subsequent corporate handling undercut accessibility, how political shifts darkened the broader landscape of rights, and how the battle for bodily autonomy is never isolated. Reproductive freedom, sexual health, workplace equality, and economic independence are interconnected. Restrict one, and the others tremble.

Chin-Yee expands the narrative beyond Eckert. Doctors and scientists challenge the long-standing dismissal of female hypoactive sexual desire disorder. Women speak candidly about losing libido and feeling erased. Their testimonies are radical precisely because they are ordinary. They insist that desire matters. Critics who argue that HSDD is over-medicalized appear as well. Their presence sharpens the debate. The film does not silence dissent. Instead, it asks who historically has had the authority to define women’s experiences as real or fabricated. Too often, that authority has rested in male-dominated institutions shaped by cultural and religious norms that prize control over autonomy.

The film’s core message is direct: Female pleasure is fundamental to health, dignity, and equality, not a trivial matter.

When political leaders legislate reproductive limits and religious authorities preach submission, the underlying logic is similar. Women’s bodies are communal property to be governed, not individual domains to be inhabited. The Pink Pill exposes how that logic infiltrates science, medicine, and law. It shows how breakthroughs in understanding female sexual response are met not just with skepticism but with attempts to contain them.

In illuminating these patterns, the film becomes more than a chronicle of one drug. It becomes a warning. Gains in gender equity are not guaranteed. They can stall. They can reverse. They can be reframed as threats to social order.

Witty, incisive, and unapologetically provocative, The Pink Pill demands that viewers confront the hypocrisy of a culture that celebrates male virility while policing female desire. It challenges the rising chorus of voices that seek to return women to narrower roles under the banner of tradition or faith. And it insists that acknowledging women as full sexual beings is not radical. It is overdue. In the end, the pink pill is not just about libido. It is about whether society is willing to accept that women’s pleasure carries weight. It deserves research, respect, and recognition. That it is not a problem to be suppressed, but a reality to be understood. The fear exposed in this film is real. So is the resolve of those who refuse to be silenced.